Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International. Chiltern is slated to fold into the company’s Covance drug development business, which conducts clinical trials for drugmakers. Get the full story at our sister site, Drug Delivery Business News.
chiltern
Diagnostics biz LabCorp to acquire contract research org Chiltern for $1.2B
(Reuters) – Diagnostics company Laboratory Corp of America Holdings said on Monday it would buy privately owned contract research organization Chiltern International Ltd for nearly $1.2 billion in cash to expand its oncology offerings. The CRO industry is undergoing a wave of consolidation as pharmaceutical companies strive to cut costs, reduce clinical trial times and expand their […]
Chiltern acquires Integrated Development Associates
Contract research organization Chiltern announced today that it is expanding its Japanese and Asian presence through its purchase of Integrated Development Associates. Financial terms of the deal were not disclosed. IDA has staff in Japan, Korea and Southeast Asia – and offers opportunities to integrate the region into global drug development, according to Chiltern. IDA’s expertise includes […]